Rebecca E. Dombrowski

FDA investigator

Appears on 14 documents from 2006 to 2019, mostly at sites in Michigan. Most often cites production record review (21 CFR 211.192).

14
Documents on file
7.5
Observations per 483
2006
First seen
2019
Most recent

What they cite most

From 90 observations

Activity by year

2006: 2, 2008: 2, 2012: 1, 2013: 3, 2015: 3, 2018: 2, 2019: 1

Where

Michigan 11 · India 2 · West Virginia 1

Is Rebecca E. Dombrowski coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

14 documents, newest first
FirmOpen
483 Sun Pharmaceutical Industries Ltd.Jun 11, 2019 · Halol, India
483 Cipla Limited Verna Industrial EstateSep 28, 2018 · Verna, India
483 Mylan Pharmaceuticals Inc.Apr 12, 2018 · Morgantown, West Virginia
483 Pfizer, Inc.Jul 23, 2015 · Rochester, Michigan
483 JHP Pharmaceuticals, Inc.Jul 23, 2015 · Rochester, Michigan
483 Pharmacia & Upjohn Company LLCJul 9, 2015 · Kalamazoo, Michigan
483 Portage Pharmacy, Inc.Mar 6, 2013 · Portage, Michigan

About this profile

What does Rebecca E. Dombrowski inspect?

Rebecca E. Dombrowski appears on 14 documents on file covering 10 sites, mostly in Michigan.

What do they cite most often?

21 CFR 211.192 (production record review), followed by 21 CFR 211.67 and 21 CFR 211.100.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Rebecca E. Dombrowski is dated Jun 11, 2019.